



3763  
JF2  
NW

Docket No. ORT-1489

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Robin THURMOND, Siquan SUN and Lars KARLSSON

Serial No.: 09/938,941 Art Unit: NOT ASSIGNED

Filed: 24 August 2001 Examiner: NOT ASSIGNED

For: **METHOD OF MONITORING THE EFFECT OF  
CATHEPSIN S INHIBITORS**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

26 November 2001

(Date of Deposit)

John W. Wallen, III, Esq.

(Name of applicant, assignee, or Registered Representative)

(Signature)

26 November 2001

(Date of Signature)

TECHNOLOGY CENTER R3700  
  
DEC 10 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.


- In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.
- In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with  the first or  second After Final Submission, therefore:
  - Statement in Accordance with §1.97(e) (attached); or
  - Please charge Deposit Account No. 10-0750/ORT-XXXX/JWW the fee of \$180.00 as set forth in §1.17(p).
- In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- Statement in Accordance with §1.97(e) (attached); or
- Please charge Deposit Account No. 10-0750/ORT-XXXX/JWW the fee of \$180.00 as set forth in §1.17(p).
- In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).
- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
  - In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
  - If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
- There are no listed references which are not in the English language.
- The relevance of those listed references which are not in the English language is as follows:
- Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

- Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT-1489/JWW. This form is submitted in triplicate.

Respectfully submitted,



John W. Wallen, III, Esq.  
Reg. No. 35,403  
Attorney for Applicants


Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, New Jersey 08933-7003  
(858) 784-3239  
DATE: 26 November 2001



**SUBMISSION UNDER MPEP 609 D**

Page 1 of 1

<i>Application Number</i>	09/938,941
<i>Filing Date</i>	24 August 2001
<i>First Named Inventor</i>	THURMOND
<i>Group Art Unit</i>	N/A
<i>Examiner Name</i>	N/A
<i>Attorney Docket Number</i>	ORT-1489



## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

#### **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		<u>Nakagawa</u> et al., "Impaired Invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S Null Mice", <i>Immunity</i> (1999) 10:207-217.	
		<u>Palmer</u> et al., "Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors", <i>J. Med. Chem.</i> (1995) 38:3193	
		<u>Riese</u> et al., "Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading", <i>Immunity</i> (1996) 4(4):357-366.	
		<u>Riese</u> et al., "Cathepsin S Activity Regulates Antigen Presentation and Immunity", <i>J. Clin. Invest.</i> (1998) 101(11):2351-2363.	
		<u>Shi</u> et al., "Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development", <i>Immunity</i> (1999) 10:197-206.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--